| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Over the last 12 months, insiders at Sensei Biotherapeutics, Inc. have bought $0 and sold $0 worth of Sensei Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sensei Biotherapeutics, Inc. have bought $2.06M and sold $1.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500 shares for transaction amount of $425 was made by Celebi John (President and CEO) on 2023‑09‑11.
| 2023-09-11 | Celebi John | President and CEO | 500 0.002% | $0.85 | $425 | -7.52% | ||
| 2023-06-01 | Sale | Apeiron Investment Group Ltd. | 10 percent owner | 955,738 3.3509% | $1.58 | $1.51M | -39.73% | |
| 2023-02-23 | Apeiron Investment Group Ltd. | 10 percent owner | 2,200 0.0071% | $1.61 | $3,539 | -36.42% | ||
| 2022-03-02 | Peyer James | 1,203 0.0037% | $3.20 | $3,850 | -49.40% | |||
| 2022-03-02 | Cambrian BioPharma Inc | 10 percent owner | 1,203 0.0037% | $3.20 | $3,850 | -49.40% | ||
| 2022-03-01 | Peyer James | 2,458 0.0082% | $3.60 | $8,849 | -51.84% | |||
| 2022-03-01 | Cambrian BioPharma Inc | 10 percent owner | 2,458 0.0082% | $3.60 | $8,849 | -51.84% | ||
| 2022-02-28 | Peyer James | 42 0.0001% | $3.60 | $151 | -52.91% | |||
| 2022-02-28 | Cambrian BioPharma Inc | 10 percent owner | 42 0.0001% | $3.60 | $151 | -52.91% | ||
| 2022-02-25 | Peyer James | 2,500 0.0079% | $3.65 | $9,125 | -54.39% | |||
| 2022-02-25 | Cambrian BioPharma Inc | 10 percent owner | 2,500 0.0079% | $3.65 | $9,125 | -54.39% | ||
| 2022-02-24 | Peyer James | 15,000 0.0483% | $3.63 | $54,450 | -53.26% | |||
| 2022-02-24 | Cambrian BioPharma Inc | 10 percent owner | 15,000 0.0483% | $3.63 | $54,450 | -53.26% | ||
| 2022-02-23 | Peyer James | 2,500 0.0082% | $3.80 | $9,500 | -54.09% | |||
| 2022-02-23 | Cambrian BioPharma Inc | 10 percent owner | 2,500 0.0082% | $3.80 | $9,500 | -54.09% | ||
| 2022-02-18 | Peyer James | 15,000 0.0473% | $3.97 | $59,550 | -56.93% | |||
| 2022-02-18 | Cambrian BioPharma Inc | 10 percent owner | 15,000 0.0473% | $3.97 | $59,550 | -56.93% | ||
| 2022-02-17 | Peyer James | 4,949 0.0164% | $4.17 | $20,637 | -56.69% | |||
| 2022-02-17 | Cambrian BioPharma Inc | 10 percent owner | 4,949 0.0164% | $4.17 | $20,637 | -56.69% | ||
| 2022-02-16 | Peyer James | 2,551 0.0083% | $4.25 | $10,842 | -57.85% |
| Cambrian BioPharma Inc | 10 percent owner | 5231488 415.0657% | $42.72M | 59 | 0 | <0.0001% |
| Peyer James | 5231488 415.0657% | $42.72M | 59 | 0 | <0.0001% | |
| RICKS THOMAS G | director | 341769 27.1159% | $2.79M | 2 | 0 | <0.0001% |
| Celebi John | President and CEO | 111311 8.8314% | $908,898.84 | 1 | 0 | <0.0001% |
| Pierce Robert Hamilton | Chief Scientific Officer | 0 0% | $0 | 0 | 4 | |
| Apeiron Investment Group Ltd. | 10 percent owner | 0 0% | $0 | 1 | 1 | <0.0001% |
Sensei Biotherapeutics, Inc. (SNSE) | $8,253,997 | 122 | -53.40% | $10.29M |
$63,749,694 | 24 | -12.24% | $9.87M | |
$1,616,354 | 20 | -12.22% | $10.66M | |
$53,355 | 19 | -41.05% | $11.08M | |
$547,862 | 19 | -29.82% | $10.86M | |
$29,469,413 | 18 | 30.40% | $9.57M | |
$8,079,884 | 14 | -43.20% | $10.5M | |
$8,971,546 | 8 | 6.18% | $11.68M | |
$232,642 | 8 | -8.03% | $8.84M | |
$603,773 | 6 | -56.12% | $8.03M | |
$73,934 | 5 | -39.52% | $9.13M | |
$126,379 | 4 | -23.04% | $9.55M | |
$1,028,395 | 4 | -11.91% | $7.89M | |
$149,611 | 4 | -25.43% | $11.11M | |
$1,057,000 | 3 | 5.27% | $11.6M | |
$7,699,992 | 2 | -74.95% | $8.52M | |
$44,529 | 2 | -30.33% | $8.28M | |
$165,600 | 2 | -3.58% | $10.91M | |
$5,512,500 | 1 | -7.91% | $11.08M |
| Increased Positions | 8 | +27.59% | 4,504 | +3.81% |
| Decreased Positions | 10 | -34.48% | 25,112 | -21.27% |
| New Positions | 4 | New | 3,087 | New |
| Sold Out Positions | 6 | Sold Out | 11,459 | Sold Out |
| Total Postitions | 27 | -6.9% | 97,474 | -17.45% |
| Ikarian Capital, Llc | $276.00 | 2.6% | 649,963 | -37 | <0.01% | 2024-12-31 |
| Vanguard Group Inc | $252.00 | 2.38% | 594,454 | -24,303 | -3.93% | 2024-12-31 |
| Catalio Capital Management, Lp | $125.00 | 1.18% | 294,374 | +294,374 | New | 2024-12-31 |
| Boothbay Fund Management, Llc | $73.00 | 0.69% | 172,798 | -37 | -0.02% | 2024-12-31 |
| Renaissance Technologies Llc | $66.00 | 0.63% | 156,800 | -58,772 | -27.26% | 2024-12-31 |
| Geode Capital Management, Llc | $63.00 | 0.6% | 148,887 | -14,252 | -8.74% | 2024-12-31 |
| Xtx Topco Ltd | $27.00 | 0.25% | 62,903 | +48,977 | +351.69% | 2024-12-31 |
| Citadel Advisors Llc | $24.00 | 0.23% | 57,717 | -8,327 | -12.61% | 2024-12-31 |
| Bridgeway Capital Management, Llc | $20.00 | 0.19% | 47,900 | 0 | 0% | 2024-12-31 |
| Susquehanna International Group, Llp | $16.00 | 0.15% | 38,051 | -52,377 | -57.92% | 2024-12-31 |